Comparison of the effects of oxycodone and sufentanil on tumor immunity, the mechanism of recurrence and metastasis in patients undergoing endoscopic liver cancer surgery

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100044387

Enrollment

Unknown

Registered

2021-03-17

Start date

2021-03-12

Completion date

Unknown

Last updated

2021-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Cancer

Interventions

Oxycodone Group:Oxycodone for intraoperative and postoperative analgesia

Sufentanil Group:Sufentanil for intraoperative and postoperative analgesia

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Aged 30-65 years old, ASA I-III grade, pathologically diagnosed I-II grade.

Exclusion criteria

Exclusion criteria: Preoperative radiotherapy and chemotherapy, severe liver dysfunction and blood coagulation dysfunction, immune system disease, distant metastasis, intraoperative use of allogeneic blood, intraoperative hypothermia (body temperature lower than 34 degree C).

Design outcomes

Primary

Measure	Time frame
pain status and pain score;Nausea and vomiting;	—

Secondary

Measure	Time frame
blood pressure and heart rate at different time points;other complications;Intake volume;Amount of bleeding;Time from drug withdrawal to extubation;Dosage of remifentanil during operation;Cortisol;TNF-alpha;IL-6;	—

Countries

China

Contacts

Public ContactYuntian Zhu

The Cancer Hospital of the University of Chinese Academy of Sciences(Zhejiang Cancer Hospital)

flyas@qq.com+86 13819497355

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026